首页> 美国卫生研究院文献>Molecular and Clinical Oncology >The combination of systemic chemotherapy and local treatment may improve the survival of patients with unresectable metastatic colorectal cancer
【2h】

The combination of systemic chemotherapy and local treatment may improve the survival of patients with unresectable metastatic colorectal cancer

机译:全身化疗与局部治疗相结合可提高无法切除的转移性结直肠癌患者的生存率

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

With the development of systemic chemotherapy, the survival time of patients with advanced colorectal cancer (CRC) has increased. In addition, local treatments, such as microwave ablation and radioactive seed implantation, have been shown to be effective. However, the number of studies reporting on the effect of systemic chemotherapy combined with local treatments is limited. The present study was conducted to determine the effect of local treatment combined with systemic chemotherapy in patients with initial unresectable metastatic CRC (mCRC). Clinicopathological and follow-up data from 273 patients with initial unresectable mCRC between April, 2007 and October, 2013 were retrospectively analyzed. A total of 51 patients received minimally invasive treatments combined with systemic chemotherapy and 39 patients achieved tumor-free survival (TFS). The median TFS time was 9 months (range, 2–45 months); the median overall survival (OS) time was 40 months (range, 12–108 months). In patients who did not achieve TFS, the OS was 37 months. Thus, patients who achieved TFS exhibited a significantly longer OS compared with those who did not achieve TFS (P=0.049). The results of the univariate analysis demonstrated that certain characteristics, such as the number of lesions and maximum tumor diameter, were associated with the achievement of TFS. The patients assessed herein achieved TFS in response to local treatments combined with systemic chemotherapy. Furthermore, the achieved TFS provided an OS benefit.
机译:随着全身化学疗法的发展,晚期大肠癌(CRC)患者的生存时间增加了。另外,已经证明局部治疗例如微波消融和放射性种子植入是有效的。但是,报告全身化疗联合局部治疗效果的研究数量有限。本研究旨在确定局部治疗联合全身化疗对最初无法切除的转移性CRC(mCRC)患者的疗效。回顾性分析了2007年4月至2013年10月之间273例最初无法切除的mCRC患者的临床病理和随访数据。共有51例患者接受了微创治疗并进行了全身化学疗法,39例患者实现了无肿瘤生存(TFS)。 TFS中位时间为9个月(2-45个月)。平均总生存时间为40个月(范围12-108个月)。未达到TFS的患者的OS为37个月。因此,与未达到TFS的患者相比,达到TFS的患者表现出明显更长的OS(P = 0.049)。单变量分析的结果表明,某些特征(如病变数目和最大肿瘤直径)与TFS的实现有关。本文评估的患者响应于局部治疗与全身化学疗法相结合而达到了TFS。此外,获得的TFS还提供了OS优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号